274 related articles for article (PubMed ID: 11303071)
1. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
[TBL] [Abstract][Full Text] [Related]
4. A potent, long-acting, orally active (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors.
Mitsuya M; Kobayashi K; Kawakami K; Satoh A; Ogino Y; Kakikawa T; Ohtake N; Kimura T; Hirose H; Sato A; Numazawa T; Hasegawa T; Noguchi K; Mase T
J Med Chem; 2000 Dec; 43(26):5017-29. PubMed ID: 11150173
[TBL] [Abstract][Full Text] [Related]
5. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
Cembala TM; Sherwin JD; Tidmarsh MD; Appadu BL; Lambert DG
Br J Pharmacol; 1998 Nov; 125(5):1088-94. PubMed ID: 9846649
[TBL] [Abstract][Full Text] [Related]
6. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
7. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
8. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.
Zhou H; Meyer A; Starke K; Gomeza J; Wess J; Trendelenburg AU
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):112-22. PubMed ID: 11819029
[TBL] [Abstract][Full Text] [Related]
10. Urinary bladder-selective action of the new antimuscarinic compound vamicamide.
Oyasu H; Yamamoto T; Sato N; Sawada T; Ozaki R; Mukai T; Ozaki T; Nishii M; Sato H; Fujiwara T
Arzneimittelforschung; 1994 Nov; 44(11):1242-9. PubMed ID: 7848339
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
12. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
13. The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor.
Ehlert FJ; Oliff HS; Griffin MT
J Pharmacol Exp Ther; 1996 Feb; 276(2):405-10. PubMed ID: 8632303
[TBL] [Abstract][Full Text] [Related]
14. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
[TBL] [Abstract][Full Text] [Related]
15. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle.
Choppin A; Eglen RM; Hegde SS
Br J Pharmacol; 1998 Jul; 124(5):883-8. PubMed ID: 9692772
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 1-methyl-5-(pyrazol-3- and -5-yl- and 1, 2, 4-triazol-3- and 5-yl)-1, 2, 3, 6-tetrahydropyridine derivatives and their evaluation as muscarinic receptor ligands.
Del Giudice MR; Mustazza C; Borioni A; Gatta F; Tayebati K; Amenta F; Tucci P; Pieretti S
Arch Pharm (Weinheim); 2003 Jun; 336(3):143-54. PubMed ID: 12822179
[TBL] [Abstract][Full Text] [Related]
19. J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors.
Mitsuya M; Mase T; Tsuchiya Y; Kawakami K; Hattori H; Kobayashi K; Ogino Y; Fujikawa T; Satoh A; Kimura T; Noguchi K; Ohtake N; Tomimoto K
Bioorg Med Chem; 1999 Nov; 7(11):2555-67. PubMed ID: 10632066
[TBL] [Abstract][Full Text] [Related]
20. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists.
Bolognesi ML; Minarini A; Budriesi R; Cacciaguerra S; Chiarini A; Spampinato S; Tumiatti V; Melchiorre C
J Med Chem; 1998 Oct; 41(21):4150-60. PubMed ID: 9767650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
